These considerations together with recent findings that illuminate the immunological nature of the therapeutic mechanism of HDI suggest that we ought not to change our attitude about the role of adjuvant high-dose IFN in high-risk melanoma patients. The gene discussed is IFNA1; the disease is melanoma.